Japan Nod For Quizartinib In First-Line AML
First FLT3 Inhibitor For Use
Executive Summary
Japan’s decision gives quizartinib its first approval globally in specific first-line AML indication, in relatively small but high-need patient population.
You may also be interested in...
From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo
When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company?
Cool Down: US FDA’s July User Fee Calendar Suggests Slower Pace After Torrid June
FDA action is expected on a handful of novel agents, including Daiichi Sankyo’s quizartinib, and conversion to full approval for Eisai/Biogen’s Leqembi.
Long Road For Daiichi Sankyo’s Quizartinib Gets Longer As FDA Extends Review Time
The drug could nevertheless find itself in a competitive position if approved for frontline FLT3-ITD acute myeloid leukemia, especially as competitor Astellas’s Xospata has repeatedly stumbled.